Evidence map›Paper›PMID 33277516›Full record

ArticleScientific reports2020

U-DCS: characterization of the first permanent human dendritic sarcoma cell line.

Kevin Mellert, Julian Benckendorff, Frank Leithäuser, Katarzyna Zimmermann, Peter Wiegand, Giada Frascaroli, Michaela Buck, Muriel Malaise, Gunther Hartmann, Winfried Barchet and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Kevin MellertInstitute of Pathology, University Hospital of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany.
Julian BenckendorffInstitute of Pathology, University Hospital of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany.
Frank LeithäuserInstitute of Pathology, University Hospital of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany.
Katarzyna ZimmermannInstitute of Pathology, University Hospital of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany.
Peter WiegandInstitute for Forensic Medicine, University Hospital Ulm, Ulm, Germany.
Giada FrascaroliInstitute of Virology, University Hospital Ulm, Ulm, Germany.
Michaela BuckInstitute of Pathology, University Hospital of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany.
Muriel MalaiseDepartment of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.
Gunther HartmannInstitute for Clinical Chemistry and Pharmacology, University of Bonn, Bonn, Germany.
Winfried BarchetInstitute for Clinical Chemistry and Pharmacology, University of Bonn, Bonn, Germany.
Daniel FürstInstitute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service, Baden Württemberg-Hessen, Ulm, Germany.
Joannis MytilineosInstitute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service, Baden Württemberg-Hessen, Ulm, Germany.
Regine Mayer-SteinackerDepartment of Internal Medicine 3, University Hospital Ulm, Ulm, Germany.
Andreas ViardotDepartment of Internal Medicine 3, University Hospital Ulm, Ulm, Germany.
Peter MöllerInstitute of Pathology, University Hospital of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany. peter.moeller@uniklinik-ulm.de.
University Hospital Ulm · DEGerman Red Cross · DEUniversity of Bonn · DEUniversity of Regensburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A dendritic cell sarcoma cell line, U-DCS, was established from a dendritic cell sarcoma in a 53-year-old Caucasian male patient. Since its establishment, U-DCS has maintained stable phenotypic characteristics in vitro and has a doubling time of approximately 2 days under standard culture conditions. U-DCS is growing with typical dendritic cell morphology in tissue and expresses the dendritic cell sarcoma immunophenotypic markers S100 protein, MHCI, MHCII, and vimentin. Expression analysis revealed transcripts for the toll-like receptors TLR3, -4, -9 and DDX58 (RIG-I), but not for TLR2. U-DCS shows functional features of dendritic cells with the ability of phagocytosis and antigen-specific T cell stimulation. Karyotype-, CGH-, and mFISH analysis point to a chromosomal instability and a hypotetraploid karyotype with approximately 130 chromosomes. U-DCS is the first immortalized human dendritic cell sarcoma cell line and has some morphological and functional features of dendritic cells without dependency on growth factors.

Indexed as

Cell Culture TechniquesCell Line, TumorChromosomal InstabilityDEAD Box Protein 58Dendritic CellsHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHumansImmunophenotypingIn Situ Hybridization, FluorescenceKaryotypeMaleMiddle AgedPhagocytosisReceptors, ImmunologicS100 ProteinsDEAD Box Protein 58Histocompatibility Antigens Class IHistocompatibility Antigens Class IIReceptors, ImmunologicRIGI protein, humanS100 ProteinsTLR3 protein, humanTLR4 protein, humanTLR9 protein, humanToll-Like Receptor 3Toll-Like Receptor 4Toll-Like Receptor 9Vimentin

Identifiers

PMID33277516
PMCPMC7718904
OpenAlexW3110484940

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.